203 results on '"Gruppo, Ralph"'
Search Results
2. Outcomes in children with deep vein thrombosis managed with percutaneous endovascular thrombolysis
3. BAY 81–8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial
4. Developing a pediatric endovascular thrombolysis program: a single-center experience
5. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening
6. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates
7. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
8. Treatment of hemophilia in developing countries: A journey of a thousand miles
9. More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome
10. Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome
11. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome
12. Favorable Histology, Mycn-Amplified 4S Neonatal Neuroblastoma
13. Clinical and molecular variability in congenital dyserythropoietic anaemia type I
14. LEGG-CALVÉ-PERTHES DISEASE AND THROMBOPHILIA
15. Protein C deficiency related to valproic acid therapy: A possible association with childhood stroke
16. Heritable Thrombophilia and Hypofibrinolysis: Possible Causes of Retinal Vein Occlusion
17. Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
18. Prophylaxis for hemophilia: State of the art or state of confusion?
19. Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation
20. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens
21. The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis
22. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures
23. Atypical Hemolytic Uremic Syndrome
24. Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)
25. Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)
26. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab
27. Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures
28. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening
29. Comparison of Multiple Electrode Impedance-Based Platelet Aggregometry to Light Transmission Aggregometry for Diagnosis of Qualitative Platelet Defects
30. Outcomes in children with deep vein thrombosis managed with percutaneous endovascular thrombolysis
31. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.
32. Integrin αIIb-Mediated PI3K/Akt Activation in Platelets
33. Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,
34. Long-Term Outcome in a Pediatric Patient with Atypical Hemolytic Uremic Syndrome (aHUS) with Sustained Eculizumab (ECU) Treatment
35. An αIIb-Mediated Outside-in Signaling Pathway That Causes Storage Granule Secretion and Thromboxane A2 Production.
36. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A
37. Abnormally sialylated fibrinogen γ-chains in a patient with chronic thromboembolic pulmonary hypertension
38. Ventilation-Perfusion Scintigraphy in Children and Adolescents Is Associated With a Low Rate of Indeterminate Studies
39. A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.
40. The β3 subunit of the integrin αIIbβ3 regulates αIIb-mediated outside-in signaling
41. The β3 Subunit of the Integrin αIibβ3 Regulates αIib-Mediated Outside-In Signaling.
42. P2-269 Homocysteine is not associated with memory and language in the nondemented oldest old
43. Population-specific alleles: the polymorphism (k121q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children
44. Low-Dose Tissue Plasminogen Activator Thrombolysis in Children
45. Hyperhomocysteinemia Is Associated With Low Plasma Pyridoxine Levels in Children With Sickle Cell Disease
46. Therapeutic choices for patients with hemophilia and high-titer inhibitors
47. Alternative Methods for Anticoagulation Monitoring in Pediatric Patients with Applicability to a Patient with Severe Hemophilia A and Circulating Inhibitor
48. Therapeutic choices for patients with hemophilia and high‐titer inhibitors
49. Distinct Domains of αIIbβ3 Support Different Aspects of Outside-In Signal Transduction and Platelet Activation Induced by LSARLAF, an αIIbβ3 Interacting Peptide
50. SEVERE PROTEIN C DEFICIENCY IN CHILDREN WHO DO NOT SURVIVE PURPURA FULMINANS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.